Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

laronidase (Aldurazyme)

laronidase is an FDA-licensed reference biologic from BioMarin Pharmaceutical Inc..

351(a) biologicBLA 125058 BioMarin Pharmaceutical Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2003

Reference product

Originator biologic
351(a)BLA 125058

Aldurazyme laronidase

BioMarin Pharmaceutical Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for laronidase from the RCSB Protein Data Bank (PDB 4MJ4).

3D molecular structure of laronidase (PDB entry 4MJ4)

Interactive biological assembly from PDB entry 4MJ4. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference laronidase product.

    23 yr 8 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    16 yr 7 mo ago

laronidase: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for laronidase.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.